Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases
The Lilly NCD Partnership will seek innovative solutions to help fight chronic diseases in developing countries
- Brazil: Hospital Israelita Albert Einstein – Diagnostic & Preventive Medicine and Research Institute
- India: The Public Health Foundation of India, Project HOPE, Population Services International
- Mexico: The Carlos Slim Health Institute – Casalud
- South Africa: The Donald Woods Foundation, Project HOPE
The Lilly NCD Partnership Approach
The new program, based on the concept of "shared value," is designed to identify comprehensive, sustainable approaches to patient care, which, depending on local needs, may include everything from patient education and provider training to increased access to treatment. The concept of "shared value," developed by Michael Porter and Mark Kramer, and originally published in the Harvard Business Review, occurs when a business identifies a select societal need and applies its business model in collaboration with others to find new solutions.
Leveraging the company's business model, the Lilly NCD Partnership will use the following methodology:
- Research: Pilot models of healthcare for diabetes based on sophisticated research and detailed data collection.
- Report: Work with well-respected partners to share data and key learnings.
- Advocate: Inform key stakeholders about program findings and encourage adoption of proven, cost-effective solutions.
"The business community can – and must – play a vital role in addressing complex societal problems. And it's clear that writing a check or donating product alone doesn't have a lasting impact," said Lechleiter. "A growing body of evidence demonstrates that when a company engages with partners in an area in which it has deep expertise and a vested interest, society benefits and the company enhances its own performance."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.